Literature DB >> 28000527

Epigenetic regulation of immune checkpoints: another target for cancer immunotherapy?

Mahmoud A Ali1, Marwa Matboli2, Marwa Tarek2, Maged Reda3, Kamal M Kamal3, Mahmoud Nouh3, Ahmed M Ashry3, Ahmed Fath El-Bab3, Hend A Mesalam4, Ayman El-Sayed Shafei5, Omar Abdel-Rahman6.   

Abstract

Epigenetic changes in oncogenes and tumor-suppressor genes contribute to carcinogenesis. Understanding the epigenetic and genetic components of tumor immune evasion is crucial. Few cancer genetic mutations have been linked to direct correlations with immune evasion. Studies on the epigenetic modulation of the immune checkpoints have revealed a critical interaction between epigenetic and immune modulation. Epigenetic modifiers can activate many silenced genes. Some of them are immune checkpoints regulators that turn on immune responses and others turn them off resulting in immune evasion. Many forms of epigenetic inheritance mechanisms may play a role in regulation of immune checkpoints including: covalent modifications, noncoding RNA and histone modifications. In this review, we will show how the potential interaction between epigenetic and immune modulation may lead to new approaches for specific epigenome/immunome-targeted therapies for cancer.

Entities:  

Keywords:  acetylation; cancer; epigenetics; immune checkpoint; lncRNA; methylation; miRNA

Mesh:

Substances:

Year:  2017        PMID: 28000527     DOI: 10.2217/imt-2016-0111

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  12 in total

1.  SUV39H1-DNMT3A-mediated epigenetic regulation of Tim-3 and galectin-9 in the cervical cancer.

Authors:  Li Zhang; Sijuan Tian; Minyi Zhao; Ting Yang; Shimin Quan; Qing Yang; Lihua Song; Xiaofeng Yang
Journal:  Cancer Cell Int       Date:  2020-07-20       Impact factor: 5.722

2.  Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab.

Authors:  Adrien Costantini; Catherine Julie; Coraline Dumenil; Zofia Hélias-Rodzewicz; Julie Tisserand; Jennifer Dumoulin; Violaine Giraud; Sylvie Labrune; Thierry Chinet; Jean-François Emile; Etienne Giroux Leprieur
Journal:  Oncoimmunology       Date:  2018-04-20       Impact factor: 8.110

3.  Precancer Atlas to Drive Precision Prevention Trials.

Authors:  Avrum Spira; Matthew B Yurgelun; Ludmil Alexandrov; Anjana Rao; Rafael Bejar; Kornelia Polyak; Marios Giannakis; Ali Shilatifard; Olivera J Finn; Madhav Dhodapkar; Neil E Kay; Esteban Braggio; Eduardo Vilar; Sarah A Mazzilli; Timothy R Rebbeck; Judy E Garber; Victor E Velculescu; Mary L Disis; Douglas C Wallace; Scott M Lippman
Journal:  Cancer Res       Date:  2017-04-01       Impact factor: 13.312

4.  Identification of Tumor Microenvironment and DNA Methylation-Related Prognostic Signature for Predicting Clinical Outcomes and Therapeutic Responses in Cervical Cancer.

Authors:  Bangquan Liu; Jiabao Zhai; Wanyu Wang; Tianyu Liu; Chang Liu; Xiaojie Zhu; Qi Wang; Wenjing Tian; Fubin Zhang
Journal:  Front Mol Biosci       Date:  2022-04-19

Review 5.  Immune checkpoint therapy in liver cancer.

Authors:  Feng Xu; Tianqiang Jin; Yuwen Zhu; Chaoliu Dai
Journal:  J Exp Clin Cancer Res       Date:  2018-05-29

6.  DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.

Authors:  Varun Sasidharan Nair; Haytham El Salhat; Rowaida Z Taha; Anne John; Bassam R Ali; Eyad Elkord
Journal:  Clin Epigenetics       Date:  2018-06-15       Impact factor: 6.551

Review 7.  Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.

Authors:  Xi Chen; Xiaohui Pan; Wenxin Zhang; Hongjie Guo; Shuyuan Cheng; Qiaojun He; Bo Yang; Ling Ding
Journal:  Acta Pharm Sin B       Date:  2019-09-25       Impact factor: 11.413

Review 8.  Targeting the Immune system and Epigenetic Landscape of Urological Tumors.

Authors:  João Lobo; Carmen Jerónimo; Rui Henrique
Journal:  Int J Mol Sci       Date:  2020-01-28       Impact factor: 5.923

9.  PD-L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance.

Authors:  Neil E Bhola; Christian Njatcha; Lanlin Hu; Eliot D Lee; Jamie V Shiah; Mi-Ok Kim; Daniel E Johnson; Jennifer R Grandis
Journal:  Head Neck       Date:  2021-08-03       Impact factor: 3.147

Review 10.  Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression.

Authors:  Reem Saleh; Salman M Toor; Varun Sasidharan Nair; Eyad Elkord
Journal:  Front Immunol       Date:  2020-07-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.